Charles River Laboratories announced the collaboration as part of an investment in Resero Analytics, a developer of data and software solutions for pharmaceutical companies, CROs and regulators.
TurboToxicology, a software tool that analyzes nonclinical data, conducts statistical analyses, applies proprietary algorithms and then formats the data into written reports.
With the use of TurboToxicology, Charles River hopes to accelerate its clients’ access to the reports required for the drug development process before they move on to submissions for Investigational New Drug (IND) or New Drug Approvals (NDA).
“Our goal is to give our clients the gift of time by alleviating some of the upfront administrative work,” said Birgit Girshick, corporate executive VP of Discovery and Safety Assessment, Biologics Testing Solutions at Charles River.
Pam Walker, corporate VP of Data and Report Delivery Services and Business Optimization at Charles River told us that TurboToxicology, “utilizes a proprietary algorithm to determine importance of findings and conduct statistical analyses while providing a user-friendly interface for our scientific staff,” Walker noted.
Financial details of the agreement were not disclosed.
